Maxim Group analyst Anthony Vendetti has maintained their neutral stance on AEMD stock, giving a Hold rating yesterday.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Anthony Vendetti’s rating is based on several factors influencing Aethlon Medical’s current position. The company has made progress in its Australian oncology trial, advancing to the second cohort after a positive safety review, which is promising. However, the decision to halt the India trial due to cost and strategic considerations reflects the challenges Aethlon faces in managing its resources effectively.
Despite these advancements, Aethlon’s financial situation remains precarious, with a cash balance of $3.8 million and an anticipated cash burn of $2.0 million per quarter, necessitating additional capital by the end of the third fiscal quarter of 2026. The absence of revenue recognition in the near term and the uncertain timeline for the commercialization of the Hemopurifier device contribute to the Hold rating. While the company’s operational discipline is commendable, the risks associated with capital constraints and clinical uncertainties make it prudent to maintain a cautious outlook.
In another report released yesterday, H.C. Wainwright also reiterated a Hold rating on the stock with a $1.50 price target.